ADORA3 and Cognitive impairment: We revealed that ADORA3 antagonist can ameliorate WMI and cognitive impairment after BCAS by improving Mertk‐mediated microglial phagocytosis to myelin debris, and Mertk‐mediated microglial phagocytosis is promoted by the activation of cAMP/PKA/p‐CREB pathway.